Earlier this week Celine Halioua (ODF2), founder and CEO of Loyal — a dog longevity biotech startup — announced something truly groundbreaking.
Loyal (ODF2) has earned what they believe to be the FDA’s first-ever formal acceptance that a drug can be developed and approved for lifespan extension.
As Celine says in her announcement; “I started Loyal 4 years ago with the explicit goal to get the first drug FDA approved for lifespan extension itself - no disease, just healthy, longer"..."We can't start selling the drug yet - we need to complete the safety and manufacturing technical sections - but this represents the lions share of the 'existential risk' of both the drug program, and of Loyal AKA - we are doing it!!!”
Laura Deming is a longevity biotech investor with an incredible batting average. 5 of 18 startups she’s backed so far have gone public. She was the first investor in Loyal and had this to say:
"This just dropped - the most important milestone in the history of longevity biotech. put simply, this is the FDA’s first-ever formal acceptance that a drug can be developed and approved to extend lifespan. the longevity field is evolving quickly. No one I know in the field would have said this was possible 5 years ago. Celine got it done in 4. It’s a massive win for both biotech founders and regulators, in establishing a pathway by which drugs (initially for dogs) can get approved for lifespan"
You’re about to listen to an archival interview with Celine just one and a half years into starting Loyal which is now 4 years old. It’s an incredible conversation with interviewer Marshall Kosloff and shows just how much can be accomplished in a few short years.
Congrats to Celine and the entire Loyal team on what is truly an unparalleled milestone.
Are you exploring starting a company we’ve got a program for that?
ODF has helped 1k companies like Loyal which was ODF2 get started and go on to raise over $2B. Applications for our 20th cohort in San Francisco are now . Learn more and apply at beondeck.com
The No-Code Revolution With Bubble’s Emmanuel Straschnov
Venture Stories: How Royal is Transforming the Artist-Fan Relationship
AI Companionship with Replika's Eugenia Kuyda
Venture Stories: Labor Marketplaces with Traba's Mike Shebat
The Network State Revisited with Balaji Srinivasan
Driving Better Health with Roundtrip's Mark Switaj
Building Health Tech in India with Loop Health's Amrit Singh
Tokenizing Creator Communities with Crowdpad's Joel Alexander
Mobile Money with Wave's CTO Ben Kuhn
The Big Tech Narrative with Alex Kantrowitz
The Market for Solutions with On Deck's Charles Cushing
The Indian Startup Ecosystem with Anand Chandrasekaran
Solarpunk Tech with Lucas Bagno and Ian Cinnamon
Embracing Hard Tech with Eli Dourado
Evolving Internet Culture with Default Friend
The Future of Focused Work with Freedom's Fred Stutzman
Personalized Wellness with Rootine's Rachel Sanders
Executive Coaching with Practice's Julien Smith
Evaluating Climate Risk with Climate X's Lukky Ahmed
The Pathless Path with Paul Millerd
Create your
podcast in
minutes
It is Free
Insight Story: Tech Trends Unpacked
Zero-Shot
Fast Forward by Tomorrow Unlocked: Tech past, tech future
The Unbelivable Truth - Series 1 - 26 including specials and pilot
Lex Fridman Podcast